Mark Talamonti to Interleukin-17
This is a "connection" page, showing publications Mark Talamonti has written about Interleukin-17.
Connection Strength
1.018
-
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert Opin Biol Ther. 2020 06; 20(6):665-672.
Score: 0.689
-
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol. 2020 Jan; 34(1):112-118.
Score: 0.166
-
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature. Dermatol Ther. 2019 05; 32(3):e12899.
Score: 0.163